Displaying drugs 6951 - 6975 of 8035 in total
Coprelotamab
Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).
Investigational
Matched Description: … Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 …
Zotatifin
Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected Advanced Solid Tumor Malignancies).
Investigational
Matched Description: … Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected …
Uliledlimab
Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).
Investigational
Matched Description: … Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for …
Lirentelimab
Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Investigational
Matched Description: … Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in …
SRP-6004
A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific promoter (rAAVrh74.MHCK7.DYSF.DV).
Investigational
Matched Description: … A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific …
JNJ-17216498
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.
Investigational
Matched Description: … JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of …
Tetraethylammonium
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide....
Experimental
Investigational
Matched Description: … The most common use of tetraethylammonium presently is as a pharmacological research agent that blocks ... Its mechanism of action is still being investigated, but it is known that tetraethylammonium blocks autonomic ... Because of its inhibitory actions at the autonomic ganglia, tetraethylammonium was thought to be a potential …
Piclamilast
Piclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. The structure for piclamilast was first elucidated in a 1995 European patent...
Experimental
Matched Description: … It has been investigated for its applications to the treatment of conditions such as chronic obstructive ... first elucidated in a 1995 European patent application and exhibits the structural functionalities of …
Rindopepimut
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted...
Investigational
Matched Description: … The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated ... injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of …
Velafermin
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple animal models. Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the...
Investigational
Matched Description: … by fostering the regeneration and repair of the cells lining the gastrointestinal tract. ... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis …
Valopicitabine
The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus (HCV) activity. Upon administration, valopicitabine is converted into 2'-C-methylcytidine; upon phosphorylation into its 5-triphosphate form, this metabolite inhibits viral RNA chain elongation and viral RNA-dependent RNA polymerase activity. This blocks viral production of HCV RNA and thus...
Experimental
Matched Description: … This blocks viral production of HCV RNA and thus viral replication. [from NCI] ... The 3-O-valine ester prodrug of the nucleoside analog 2'-C-methylcytidine with anti-hepatitis C virus …
Erythroxylum catuaba bark
"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the Erythroxylum genus, though this name is also applied to infusions of plants belonging to other genera. The infusion is thought to carry stimulant and aphrodisiac effects, and catuaba made specifically with Trichilia...
Experimental
Matched Description: … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _ ... Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera …
CVnCoV Vaccine
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … Phase 1 clinical trials of this vaccine (NCT04449276). ... As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence …
Fenretinide
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Investigational
Matched Description: … synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of …
VIR201
is an experimental therapeutic vaccine currently in clinical trial. The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent progression to AIDS.
Investigational
Matched Description: … The aim of therapeutic vaccines is to augment the body's immune response to HIV and to delay or prevent …
(S)-Fluoxetine
An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).
Experimental
Matched Description: … has S configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of …
Rociletinib
Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer, Non-small Cell Lung Cancer, and Locally Advanced or Metastatic Non-small Cell Lung Cancer.
Investigational
Matched Description: … Rociletinib has been used in trials studying the treatment and prevention of Nonsmall Cell Lung Cancer …
6-O-benzylguanine
6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.
Investigational
Matched Description: … 6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, …
Cepeginterferon alfa-2B
Cepeginterferon alfa-2B is under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C).
Investigational
Matched Description: … under investigation in clinical trial NCT01889433 (An Open-label Comparative Efficacy and Safety Study of …
Metampicillin
Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. It is hydrolysed in aqueous solution to form ampicillin. Hydrolysis is rapid under acid conditions like the stomach.
Experimental
Matched Description: … Metampicillin is a penicillin antibiotic prepared by the reaction of ampicillin with formaldehyde. …
GO-203-2C
GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Description: … GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor …
Mongersen
Mongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects).
Investigational
Matched Description: … Mongersen is under investigation in clinical trial NCT02957474 (A Study to Evaluate the Effect of Food …
Tuspetinib
Tuspetinib (HM-43239) is under investigation in clinical trial NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia).
Investigational
Matched Description: … NCT03850574 (Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of …
Sabatolimab
Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
Investigational
Matched Description: … Sabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With …
INM004
INM004, a Neutralizing Equine Anti-Stx Hyperimmune Immunoglobulin F(Ab')2 Fragment, is currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of hemolytic uremic syndrome.
Investigational
Matched Description: … currently being investigated to treat Shiga-toxin producing bacterial infection relating to the prevention of …
Displaying drugs 6951 - 6975 of 8035 in total